Gene editing gets more and finer tools
Despite the hoopla, the accuracy of CRISPR-based approaches has raised concerns among academics, clinicians and regulators. The ability...
Contributors
-
Joint Head of Behavioural Science -
Account Manager -
-
Associate Consultant -
-
Joint Head of Behavioural Science -
President, USA -
Vice President, Business Development -
Senior Consultant -
-
Publications Executive -
Project Director -
-
Strategic Communications Director -
Associate Consultant -
Executive Chairman -
Consultant -
-
CEO -
-
Senior Consultant -
Consultant -
Senior Consultant -
-
SVP -
Master Practitioner: Patient Insights -
Publications Assistant -
EVP, Oncology Practice Head -
EVP, Patient Solutions -
-
US CEO -
-
Associate Editorial Director
-
Sr. Research Analyst -
-
Principal -
Research Executive -
Account Director -
-
-
Head of MedErgy (CH-MedErgy) -
-
Managing Consultant -
Project Manager -
Project Director -
Executive Vice President, Strategic Collaborations -
Associate Consultant
Cello Health Archive
- November 2021 (2)
- October 2021 (1)
- August 2021 (2)
- July 2021 (2)
- April 2021 (3)
- March 2021 (4)
- January 2021 (1)
- December 2020 (1)
- November 2020 (1)
- October 2020 (2)
- September 2020 (3)
- August 2020 (6)
- July 2020 (3)
- June 2020 (1)
- May 2020 (1)
- April 2020 (2)
- March 2020 (6)
- February 2020 (19)
- January 2020 (4)
- December 2019 (3)
- November 2019 (4)
- October 2019 (1)
- September 2019 (2)
- August 2019 (4)
- July 2019 (4)
- June 2019 (4)
- May 2019 (12)
- April 2019 (11)
- March 2019 (5)
- February 2019 (12)
- January 2019 (1)
- October 2018 (2)
- August 2018 (5)
- July 2018 (7)
- June 2018 (5)
- May 2018 (5)
- April 2018 (6)
- March 2018 (9)
- February 2018 (11)
- January 2018 (4)
- December 2017 (8)
- November 2017 (21)
- October 2017 (35)
- September 2017 (18)
- August 2017 (1)
- July 2017 (1)
- June 2017 (1)
- May 2017 (2)
- April 2017 (2)
- March 2017 (1)
- February 2017 (2)
- January 2017 (1)
- December 2016 (1)
- October 2016 (1)
The challenging dynamism of cancer
Recognition of cancer's heterogeneity is not new. But time and again when looking at clinical trial designs and even preclinical modeling...
Wearables are increasing in popularity, but do they have real health benefits?
In questioning the health benefit of wearables, the article below touches upon some recent positive trends. For instance, insurers...
Is Gilead likely to catch Intercept in the race for treatment for NASH patients?
Non-alcoholic Steatohepatitis (NASH), although one of the leading causes for liver transplant is a mostly forgotten disease. Despite...
The relevance of microbiomes to disease and our health
The Human Microbiome Project was launched by the National Institutes of Health in 2007 yet there is still much to be known about...
What can we learn from a sea cucumber?
The curious habit of vomiting its viscera at predators may mean the lowly sea cucumber holds the key to a clearer understanding of the...
CAR-Ts: Changing the game in cancer treatment
CAR-T therapies are one of the most recently developed revolutionary cancer treatments and certainly one of the most hyped innovations in...
Could depression be an immunological response?
Recent research has found correlation between someone undergoing major depressive episodes with neuroinflammation based on microglial...
Is AI the answer to patient-centric pharmaceutical strategy?
“How will AI change strategy?” The opening line to an interesting thought experiment written by the Harvard Business Review. In the...
Are 'hot' tumours better for you?
Immuno-oncology has seen a rapid growth in the past few years in terms of not only research, clinical development and investment but also...
Should I continue taking PPIs?
The microbiome, the complex community of micro-organisms such as bacteria, fungi, and viruses and their genes is a hot topic at the moment.
Could this collaboration be the step forward for the diagnosis of many under-served patients?
Qiagen, a sample to insight molecular testing company, has joined forces with Centogene, owners of CentoMD. CentoMD is the largest...
Is $22m enough to stimulate rare disease drug development?
The FDA awarded $22 million across 15 clinical trial grants to help increase rare disease drug development. Fantastic! But is it enough?
A...
Will Amazon crack drug distribution?
After turning its attention from home delivery of almost anything you can imagine, perhaps it's not surprising that media reports are...
How Scientists Use Light to Turn Off Autism Symptoms in Mice
Optogenetics, a technique which involves the use of light to control neurons, has been successfully used in mice to restore stability...
22 innovations driving digital health in the UK
The UK health industry is fuelled by pioneers. It may not always seem it, but through every sector of health, there are industrious...
Is regenerative medicine the 'Wild West' of modern science?
A recent report published in The Lancet calls for a coordinated strategy to reform the science and policy behind stem cells and...
Noninferiority Trials
NEJM article makes a case for a fresh approach to design and interpretation of noninferiority trials in the context of today's...
How genomic data uncovered a disease that eluded doctors for years
Discoveries around genomics and partnerships related to genomic data have recently been making headlines with Sophia Genetics raising $30...
HIV-delivered gene therapy halts rare brain disease
Adrenoleukodystrophy (ALD) is a rare hereditary mutation and neurodegenerative disease that affects about 0.005% of young boys, and has...
Increased noise around mental health
It seems to be the thing we are all talking about and breaking down the barriers can only be a good thing. However it must be noted that...
Pediatric devices that grow up? Potential challenges and impact
Medical implants are typically not designed for pediatrics. This is partially due to current implant technologies inability to...
Why race matters in genomic sequencing
The mapping of the genome is considered to be one of the greatest medical advances of the 21st century so far. It is easy to see why,...
Can digital health be the answer for mental health?
The UK Royals have pledged £2 million to a new digital mental health initiative. Celebrities are speaking out about their challenges with...
A treatment for myleodysplastic syndromes
Myleodysplastic syndromes (MDS) affects haematopoiesis within its sufferers, this leads to severe anaemia. Currently the way that the...
Is the Microbiome all Hype?
There is considerable interest and excitement about the human microbiome, the complex community of micro-organisms such as bacteria,...
Pharma talks value-based payments and digital opportunity at Health 2.0
A great glimpse into of some the stimulating conversations among pharma innovation leaders this past week at the Health 2.0 Annual Fall...
Can bioelectronics replace biopharmaceuticals?
Treating autoimmune disorders has been a cash cow for several pharmaceutical companies, with biologics and biosimilars dominating pharma...
Will RNAi delivery systems herald in a new era of drugs that shut down troublesome genes?
News of Alnylam's experimental RNAi drug thrilled both patients and scientists, who have been working for over a decade to create a drug...
Cybersecurity for medical devices
Cost pressures, ongoing consolidation, increasing sophistication of customers, and digitalization of health care present unprecedented...
Additional novel modes for nonviral delivery of CRISPR
Though CRISPR/Cas9 has shown great potential for genetic modification in various therapies, deliverying the platform has been a key...
'Hype' and 'Hope' of genomic medicine
Back in April 2003, the Human Genome Project, which was one of the great feats of exploration in human history, was completed. This...
A pleasant surprise in the Fierce 15: BlackThorn Therapeutics
It has been a year filled with innovation and exciting technology in the healthcare sector. From the focus on CRISPR to the first...
Immunotherapy - the fifth pillar in cancer treatment
The emergent success of immune-oncology (IO) drug approvals in multiple tumours has appointed it as the fifth pillar in cancer treatment.
6 steps to predicting future of Pharma
“The microbiome: opportunity or hype?” - My latest iPhone notification reflects the daily evolution of our industry: increased...
As a free user, you can follow Passle and like posts.
To repost this post to your own Passle blog, you will need to upgrade your account.
For plans and pricing, please contact our sales team at sales@passle.net